Molecular Diagnostics

A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy

Abstract

Background

A pre-specified model based on four kallikrein markers in blood, commercially available as 4Kscore, predicts Gleason Grade (GG) 3 + 4 or higher prostate cancer on biopsy. However, sampling error and variation in pathology reporting may miss aggressive disease.

Methods

The 4Kscore was measured in cryopreserved blood from 2330 men obtained before prostatectomy at a single institution between 2002 and 2010. Adverse surgical pathology and biochemical recurrence (BCR) were pre-specified to be assessed in all men, biopsy GG 3 + 3, and 3 + 4.

Results

Adjusted for established clinical predictors, the 4Kscore was significantly associated with adverse pathology (OR 1.49; 95% CI 1.32, 1.67; p < 0.0001). Adding 4Kscore increased discrimination from (AUC) 0.672 to 0.718 and 0.644 to 0.659 within biopsy GG 3 + 3 and 3 + 4, respectively. Higher 4Kscore was associated with higher risk of BCR (HR 1.16, 95% CI 1.06, 1.26; p = 0.001). Adding 4Kscore improved the prediction of BCR (C-index 0.630–0.660) within GG 3 + 3, but not GG 3 + 4.

Conclusions

The 4Kscore can help guide the clinical decision whether additional risk assessment—such as confirmatory biopsy—is needed to decide between active surveillance versus curative therapy. Evidence that the panel could influence management in biopsy GG 3 + 4 is less strong and requires further investigation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Decision curve analysis based on Gleason Grade.
Fig. 2: Risk of adverse pathology and distribution of 4Kscore based on Gleason Grade.

References

  1. 1.

    Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027–2035 (2014).

    Article  Google Scholar 

  2. 2.

    Ehdaie, B., Vertosick, E., Spaliviero, M., Giallo-Uvino, A., Taur, Y., O’Sullivan, M. et al. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J. Urol. 191, 660–664 (2014).

    Article  Google Scholar 

  3. 3.

    Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R. et al. Systematic review of complications of prostate biopsy. Eur. Urol. 64, 876–892 (2013).

    Article  Google Scholar 

  4. 4.

    Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277 (2015).

    Article  Google Scholar 

  5. 5.

    Kinsella, N., Helleman, J., Bruinsma, S., Carlsson, S., Cahill, D., Brown, C. et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl. Androl. Urol. 7, 83–97 (2018).

    Article  Google Scholar 

  6. 6.

    Kaye, D. R., Qi, J., Morgan, T. M., Linsell, S., Ginsburg, K. B., Lane, B. R. et al. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU Int. 123, 846–853 (2018).

    Article  Google Scholar 

  7. 7.

    Epstein, J. I., Feng, Z., Trock, B. J. & Pierorazio, P. M. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur. Urol. 61, 1019–1024 (2012).

    Article  Google Scholar 

  8. 8.

    Chun, F. K., Briganti, A., Shariat, S. F., Graefen, M., Montorsi, F., Erbersdobler, A. et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 98, 329–334 (2006).

    Article  Google Scholar 

  9. 9.

    Reichard, C. A., Stephenson, A. J. & Klein, E. A. Applying precision medicine to the active surveillance of prostate cancer. Cancer 121, 3403–3411 (2015).

    Article  Google Scholar 

  10. 10.

    Sternberg, I. A., Vela, I. & Scardino, P. T. Molecular profiles of prostate cancer: to treat or not to treat. Annu Rev. Med. 67, 119–135 (2016).

    CAS  Article  Google Scholar 

  11. 11.

    Parekh, D. J., Punnen, S., Sjoberg, D. D., Asroff, S. W., Bailen, J. L., Cochran, J. S. et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur. Urol. 68, 464–470 (2015).

    Article  Google Scholar 

  12. 12.

    Punnen, S., Pavan, N. & Parekh, D. J. Finding the wolf in sheep’s clothing: the 4Kscore is a novel blood test that can accurately identify the risk of aggressive prostate cancer. Rev. Urol. 17, 3–13 (2015).

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Punnen, S., Freedland, S. J., Polascik, T. J., Loeb, S., Risk, M. C., Savage, S. et al. A multi-institutional prospective trial confirms noninvasive blood test maintains predictive value in African American men. J. Urol. 199, 1459–1463 (2018).

    Article  Google Scholar 

  14. 14.

    Vickers, A. J., Vertosick, E. A. & Sjoberg, D. D. Value of a statistical model based on four kallikrein markers in blood, commercially available as 4Kscore, in all reasonable prostate biopsy subgroups. Eur. Urol. 74, 535–536 (2018).

    Article  Google Scholar 

  15. 15.

    Sjoberg, D. D., Vickers, A. J., Assel, M., Dahlin, A., Poon, B. Y., Ulmert, D. et al. Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men. Eur. Urol. 73, 941–948 (2018).

    Article  Google Scholar 

  16. 16.

    Stattin, P., Vickers, A. J., Sjoberg, D. D., Johansson, R., Granfors, T., Johansson, M. et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur. Urol. 68, 207–213 (2015).

    CAS  Article  Google Scholar 

  17. 17.

    Vickers, A. J., Gupta, A., Savage, C. J., Pettersson, K., Dahlin, A., Bjartell, A. et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol. Biomark. Prev. 20, 255–261 (2011).

    CAS  Article  Google Scholar 

  18. 18.

    Vaisanen, V., Peltola, M. T., Lilja, H., Nurmi, M. & Pettersson, K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab’)2 fragments. Anal. Chem. 78, 7809–7815 (2006).

    Article  Google Scholar 

  19. 19.

    Brand, T. C., Zhang, N., Crager, M. R., Maddala, T., Dee, A., Sesterhenn, I. A. et al. Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene genomic prostate score. Urology 89, 69–75 (2016).

    Article  Google Scholar 

  20. 20.

    Bryant, R. J., Sjoberg, D. D., Vickers, A. J., Robinson, M. C., Kumar, R., Marsden L. et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J. Natl Cancer Inst. 107, djv095 (2015).

  21. 21.

    Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Med Decis. Mak. 26, 565–574 (2006).

    Article  Google Scholar 

  22. 22.

    Wenske, S., Korets, R., Cronin, A. M., Vickers, A. J., Fleisher, M., Scher, H. I. et al. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J. Cancer 124, 659–663 (2009).

    CAS  Article  Google Scholar 

  23. 23.

    Haese, A., Graefen, M., Becker, C., Noldus, J., Katz, J., Cagiannos, I. et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 54, 181–186 (2003).

    CAS  Article  Google Scholar 

  24. 24.

    Haese, A., Graefen, M., Steuber, T., Becker, C., Pettersson, K., Piironen, T. et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 49, 101–109 (2001).

    CAS  Article  Google Scholar 

  25. 25.

    Haese, A., Becker, C., Noldus, J., Graefen, M., Huland, E., Huland, H. et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J. Urol. 163, 1491–1497 (2000).

    CAS  Article  Google Scholar 

  26. 26.

    Carlsson, S., Maschino, A., Schroder, F., Bangma, C., Steyerberg, E. W., van der Kwast, T. et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur. Urol. 64, 693–699 (2013).

    CAS  Article  Google Scholar 

  27. 27.

    Punnen, S., Nahar, B., Prakash, N. S., Sjoberg, D. D., Zappala, S. M. & Parekh, D. J. The 4Kscore predicts the grade and stage of prostate cancer in the radical prostatectomy specimen: results from a multi-institutional prospective trial. Eur. Urol. Focus 3, 94–99 (2017).

    Article  Google Scholar 

  28. 28.

    Lin, D. W., Newcomb, L. F., Brown, M. D., Sjoberg, D. D., Dong, Y., Brooks, J. D. et al. Evaluating the four kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer in men in the canary prostate active surveillance study. Eur. Urol. 72, 448–454 (2017).

    CAS  Article  Google Scholar 

  29. 29.

    Borque-Fernando, A., Rubio-Briones, J., Esteban, L. M., Dong, Y., Calatrava, A., Gomez-Ferrer, A. et al. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 22, 84–90 (2018).

    Article  Google Scholar 

  30. 30.

    Sauter, G., Steurer, S., Clauditz, T. S., Krech, T., Wittmer, C., Lutz, F. et al. Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. Eur. Urol. 69, 592–598 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author information

Affiliations

Authors

Contributions

A.H. conceived the idea, acquired the data and revised the paper. A.T. analysed and interpreted the data, carried out the statistical analysis, drafted and revised the paper. S.C. interpreted the data and drafted the paper. D.S. interpreted the results and revised the paper. D.P. acquired data and revised the paper. T. Steuber conceived the idea and revised the paper. H.H. conceived the idea and revised the paper. M.G. conceived the idea and revised the paper. P.S. conceived the idea and revised the paper. T. Schlomm conceived the idea and revised the paper. A.V. conceived and designed the idea, analysed and interpreted the data and revised the paper. H.L. conceived and designed the idea, interpreted the data and revised the paper. G.S. conceived the idea and revised the paper.

Corresponding author

Correspondence to Hans Lilja.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was obtained from the MSKCC IRB. Consent was not sought from participants for this retrospective biomarker study as this was waived by the IRB. The study was performed in accordance with the Declaration of Helsinki.

Consent to publish

Not applicable.

Data availability

The data sets analysed for this study will be made available to researchers on reasonable request to the corresponding author.

Competing interests

Hans Lilja holds patents on assays for free PSA, intact PSA and hK2. Andrew Vickers, Hans Lilja, and Peter Scardino are named on a patent for a statistical method to detect prostate cancer (the 4KScore test) that has been commercialised by OPKO Health. Andrew Vickers, Hans Lilja and Peter Scardino receive royalties from sales of the test. Hans Lilja and Peter Scardino have stock, and Andrew Vickers has stock options in OPKO Health. Sigrid Carlsson has received a lecture honorarium and travel support from Astellas Pharma (unrelated to the current study). The other authors declare no other competing interests.

Funding information

This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], a SPORE grant in Prostate Cancer to Dr. H. Scher [P50 CA092629], the Sidney Kimmel Center for Prostate and Urologic Cancers, David H. Koch through the Prostate Cancer Foundation. This work was also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Program in the United Kingdom, the Swedish Cancer Society (CAN 2017/559), the Swedish Research Council (VR-MH project no. 2016-02974) and General Hospital in Malmö Foundation for Combating Cancer.

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Haese, A., Tin, A.L., Carlsson, S.V. et al. A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-0914-7

Download citation